These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22038993)

  • 1. Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.
    Fleuren ED; Versleijen-Jonkers YM; van de Luijtgaarden AC; Molkenboer-Kuenen JD; Heskamp S; Roeffen MH; van Laarhoven HW; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
    Clin Cancer Res; 2011 Dec; 17(24):7693-703. PubMed ID: 22038993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.
    Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT
    Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507.
    Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Bouwman WH; van der Graaf WT; Oyen WJ; Boerman OC
    Mol Pharm; 2012 Aug; 9(8):2314-21. PubMed ID: 22747077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
    Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Oyen WJ; van der Graaf WT; van Laarhoven HW
    Int J Cancer; 2013 Jul; 133(2):307-14. PubMed ID: 23335047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model.
    Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Franssen GM; Versleijen-Jonkers YM; Oyen WJ; van der Graaf WT; Boerman OC
    J Nucl Med; 2010 Oct; 51(10):1565-72. PubMed ID: 20847162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
    Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R
    Pediatr Blood Cancer; 2010 Jul; 55(1):67-75. PubMed ID: 20486173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.
    England CG; Kamkaew A; Im HJ; Valdovinos HF; Sun H; Hernandez R; Cho SY; Dunphy EJ; Lee DS; Barnhart TE; Cai W
    Mol Pharm; 2016 Jun; 13(6):1958-66. PubMed ID: 27054683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy.
    Ferté C; Loriot Y; Clémenson C; Commo F; Gombos A; Bibault JE; Fumagalli I; Hamama S; Auger N; Lahon B; Chargari C; Calderaro J; Soria JC; Deutsch E
    Mol Cancer Ther; 2013 Jul; 12(7):1213-22. PubMed ID: 23640142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study.
    Pappo AS; Vassal G; Crowley JJ; Bolejack V; Hogendoorn PC; Chugh R; Ladanyi M; Grippo JF; Dall G; Staddon AP; Chawla SP; Maki RG; Araujo DM; Geoerger B; Ganjoo K; Marina N; Blay JY; Schuetze SM; Chow WA; Helman LJ
    Cancer; 2014 Aug; 120(16):2448-56. PubMed ID: 24797726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
    Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
    PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.
    van Rij CM; Sharkey RM; Goldenberg DM; Frielink C; Molkenboer JD; Franssen GM; van Weerden WM; Oyen WJ; Boerman OC
    J Nucl Med; 2011 Oct; 52(10):1601-7. PubMed ID: 21865288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule.
    Su X; Cheng K; Liu Y; Hu X; Meng S; Cheng Z
    Amino Acids; 2015 Jul; 47(7):1409-19. PubMed ID: 25854877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
    Schwartz GK; Tap WD; Qin LX; Livingston MB; Undevia SD; Chmielowski B; Agulnik M; Schuetze SM; Reed DR; Okuno SH; Ludwig JA; Keedy V; Rietschel P; Kraft AS; Adkins D; Van Tine BA; Brockstein B; Yim V; Bitas C; Abdullah A; Antonescu CR; Condy M; Dickson MA; Vasudeva SD; Ho AL; Doyle LA; Chen HX; Maki RG
    Lancet Oncol; 2013 Apr; 14(4):371-82. PubMed ID: 23477833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
    Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
    Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of IGF-1R expression during endocrine breast cancer treatment.
    Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Koornstra RH; Linn SC; Oyen WJ; van der Graaf WT; van Laarhoven HW
    Mol Imaging Biol; 2014 Aug; 16(4):529-37. PubMed ID: 24532107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
    Cornelissen B; McLarty K; Kersemans V; Reilly RM
    Nucl Med Biol; 2008 Aug; 35(6):645-53. PubMed ID: 18678349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.
    McKinley ET; Bugaj JE; Zhao P; Guleryuz S; Mantis C; Gokhale PC; Wild R; Manning HC
    Clin Cancer Res; 2011 May; 17(10):3332-40. PubMed ID: 21257723
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.